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1. Introduction 
Cystic Fibrosis (CF) is the most commonly inherited potentially lethal disease amongst 
Caucasian children and young adults. In Europe, approximately 35,000 children and adults 
are affected by CF. The prevalence in the US and in Canada is approximately 30,000 and 
3,000, respectively. CF is an autosomal recessive disorder and is caused by mutations in the 
Cystic Fibrosis Transmembrane Conductance Regulator gene (CFTR) (Riordan, Rommens et 
al. 1989). The main function of CFTR in many tissues is to regulate and participate in the 
transport of chloride ions across epithelial cell membranes. To date, more than 1,800 
mutations have been described in this gene, but the most common mutation worldwide is 
caused by deletion of phenylalanine at position 508 (Delta F508) of the CFTR on 
chromosome 7. The dramatic improvement in survival from CF has taken great strides over 
the past 40 years with the introduction of specialist centre care, optimising nutritional status 
and preventing pulmonary inflammation. The median survival of children born in the 1990s 
is estimated to exceed 40 years of age with more than 85% of them achieving adulthood. CF 
is a multisystem disorder and is characterised by chronic suppurative lung disease and by 
exocrine pancreatic insufficiency which affects gastrointestinal function and causes 
restricted growth and maturation. CF also causes obstructive azoospermia and thus male 
infertility. However, in most individuals with CF the major burden is on the lungs. The 
absence of CFTR in airway epithelium leads to malfunction of chloride conductance and 
subsequent airway surface liquid (ASL) volume reduction, mucins are concentrated, the 
periciliary liquid depleted, and mucous clearance by ciliary and cough dependent 
mechanisms diminished, which leads to airflow obstruction and eventually bacterial 
colonisation.  Bacteria implicated in the morbidity and mortality of CF include Pseudomonas 
aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Staphylococcus aureus, 
Haemophilus influenzae, Stenotrophomonas maltophilia and non-tuberculous mycobacteria. 
However despite the appropriate use of antibiotic therapy, chronic obstructive airway 
disease continues to develop in patients with CF and is the major cause of morbidity and 
mortality.  
However, the use of appropriate antibiotic therapy has had a limited effect in slowing the 
progression of pulmonary disease. As a result, recent studies have hypothesised that 
respiratory viral infection may be a contributing factor to pulmonary exacerbations. 
Respiratory viruses implicated in the respiratory exacerbations of CF include influenza A and 
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B, respiratory syncytial virus (RSV), parainfluenza virus (PIV) types 1 to 4, rhinovirus, 
metapneumovirus, coronavirus and adenovirus. 
The role of respiratory viruses in the aetiology of respiratory exacerbations in CF is not 
fully understood and may have been underestimated as many previous studies have 
used insensitive techniques  to isolate respiratory viruses, therefore undermining their 
prevalence. New viral detection techniques have further enhanced the awareness of 
respiratory viral aetiology in CF exacerbations. A recent in vitro study illustrating the 
interaction of respiratory virus and P. aeruginosa may contribute to the pathogenesis of 
CF exacerbations. No doubt more work will be required in this area to further 
understand their relationship so as to allow the development of potential novel 
treatment. If respiratory viruses do lead to secondary bacterial infection in CF, this may 
rationalize the treatment of CF in future. Although there are commercially available 
vaccines and anti-virals for the prevention and treatment of respiratory viral infections, 
they are mainly limited to influenza viral infection. A number of studies are currently 
underway looking at the development of new vaccines and anti-virals, hopefully it will 
not be long before treatment becomes available for different types of respiratory 
viruses. 
This chapter will provide an overview on the epidemiology of respiratory viruses in CF, the 
available detection techniques for viruses and their differences in sensitivities, the clinical 
implications of viral infection in CF, the interaction between viruses and bacteria, and the 
management of viral infections. 
CF is the most commonly inherited, potentially lethal disease amongst Caucasian children 
and young adults (Mearns 1993). Pathological changes occur in all exocrine glands (Vawter 
and Shwachman 1979), however, in most individuals with CF the major impact is on the 
lungs (Oppenheimer and Esterly 1975). Chronic lung infections may start very early in the 
lives of patients with CF. It has been hypothesised that impaired mucociliary clearance and 
low airway surface liquid (ASL) volume is pivotal for the pathogenesis of lung infections. 
These in turn lead to impaired bacterial clearance from respiratory epithelial cells (Saiman 
and Siegel 2004). Pulmonary infections remain to be the greatest cause of morbidity and 
mortality leading to premature death in CF (Rajan and Saiman 2002). 
The incidence of CF in the United Kingdom is around 1 in 2500 live births and 1 in 25 of the 
population carry a mutation in their CF genes (Dodge, Morison et al. 1993). CF is a 
multisystem disorder and is characterised by chronic suppurative lung disease and by 
exocrine pancreatic insufficiency which affects gastrointestinal function and causes 
restricted growth and maturation. CF also causes obstructive azoospermia and thus male 
infertility. 
CF is an autosomal recessive disorder and is caused by mutations in the CFTR (Riordan, 
Rommens et al. 1989). The main function of CFTR in many tissues is to regulate and 
participate in the transport of chloride ions across epithelial cell membranes (Barasch and al-
Awqati 1993). So far more than 1,800 mutations have been described in this gene 
(http://genet.sickkids.on.ca/cgi-bin/WebObjects/MUTATION), but the most common 
mutation worldwide is caused by deletion of phenylalanine at position 508 (Delta F508) of 
the CFTR on chromosome 7.  
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Survival from CF is increasing rapidly as exemplified by the median life expectancy of CF 
children born in 1990 to be around 40 years which is double that of 20 years ago (Elborn, 
Shale et al.). The prolonged life expectancy might be attributed to multi-disciplinary care, 
improved nutritional status, use of antibiotics and better understanding of disease 
pathology.  
CF pulmonary exacerbations represent decreased host defences within the lungs leading to 
alterations in airway microbiology, airway obstruction related to increased sputum 
production and ventilatory failure (Goss and Burns 2007). Pulmonary exacerbations are 
associated with acquisition of new organisms and increased concentration of airway flora 
(Aaron, Ramotar et al. 2004). The presences of some organisms including S. aureus, P. 
aeruginosa and B. cepacia in the airways have been shown to lead to clinical deterioration 
(Thomassen, Demko et al. 1985; Nixon, Armstrong et al. 2001; Sawicki, Rasouliyan et al. 
2008). The new acquisitions of P. aeruginosa in CF have been demonstrated to occur in the 
winter months coinciding with the peak of respiratory viral infections (Johansen and Hoiby 
1992). Influenza is a substantial health threat, it is associated with approximately >36,000 
deaths and 220,000 hospitalisations in the United States yearly (Thompson, Shay et al. 2004). 
The emergence of novel influenza virus (H1N1) further heightened the awareness of 
influenza-like illness. CF Pulmonary exacerbation rates have been shown to be significantly 
increased during the winter and are highly associated with the influenza season (Ortiz, 
Neuzil et al. 2010).  
2. Viral respiratory infections in CF 
Early studies looking at respiratory viruses in CF relied on repeated serological testing, 
either alone (Petersen, Hoiby et al. 1981) or in combination with viral cultures for viral 
detection (Wang, Prober et al. 1984; Ramsey, Gore et al. 1989; Pribble, Black et al. 1990; 
Armstrong, Grimwood et al. 1998; Hiatt, Grace et al. 1999). These methods are relatively 
insensitive and more recent studies have utilised PCR based methodologies (Smyth, Smyth 
et al. 1995; Collinson, Nicholson et al. 1996; Punch, Syrmis et al. 2004; Olesen, Nielsen et al. 
2006; Wat, Gelder et al. 2008). All these studies produced different results in terms of 
prevalence of respiratory viruses in CF. The differences can be due to different 
methodologies. There are also likely to be differences in the populations studied as the 
prognosis for CF has improved with each successive birth cohort. 
The viruses implicated in causing respiratory symptoms in CF include RSV, adenovirus, PIV 
(Types 1 to 4) , influenza A&B, rhinovirus (Ramsey, Gore et al. 1989; Smyth, Smyth et al. 1995; 
Collinson, Nicholson et al. 1996; Wat, Gelder et al. 2008) and more recently metapneumovirus 
(Garcia, Hiatt et al. 2007). RSV represents 9-58% of all reported viral infection in CF, with the 
highest incidence in young children (Armstrong, Grimwood et al. 1998). It is possible that 
RSV precipitates in the initial infection by P. aeruginosa of the CF airway(Petersen, Hoiby et 
al. 1981), the proposed mechanism of which will be discussed later. A new subtype of 
human rhinovirus was recently identified, rhinovirus C, and was shown by de Almeida et al 
(de Almeida, Zerbinati et al. 2010) that it is significantly associated with respiratory 
exacerbations in children with CF (Odd ratio- 1.213). Influenza A and B take 12-27%, but in 
one small study, it comprised of 77% of positive samples (Hordvik, Konig et al. 1989). PIV 
are found in lower frequencies with only one study showing a detection rate of 43% from 
positive samples (Petersen, Hoiby et al. 1981). Metapneumovirus has recently been detected in 
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nasopharyngeal aspirates taken from hospitalised children and infants with respiratory tract 
infections who had signs and symptoms similar to those of RSV infection (van den Hoogen, 
de Jong et al. 2001). This virus is also associated with lower respiratory tract infections in 
patients with CF (Garcia, Hiatt et al. 2007). 
It is now nearly 30 years since Wang et al (Wang, Prober et al. 1984) described the 
relationship between respiratory viral infections and deterioration in clinical status in CF. In 
this 2 year prospective study (Wang, Prober et al. 1984), viruses were identified through 
repeated serology and nasal lavage for viral isolation in 49 patients with CF (mean age 13.7 
years). Although the CF patients had more respiratory illnesses than sibling controls (3.7 
versus 1.7/year), there were no differences in virus identification rates (1.7/year). The rate 
of proven virus infection was significantly correlated with the decline in lung functions, 
radiology score, and frequency and duration of hospitalisation.  
More recent studies suggest no difference in the frequency of either upper respiratory tract 
illness (URTI) episodes (Hiatt, Grace et al. 1999) or proven respiratory viral infections (Ramsey, 
Gore et al. 1989) between children with CF and healthy controls, but children with CF have 
significantly more episodes of lower airway symptoms than controls (Ramsey, Gore et al. 1989; 
Hiatt, Grace et al. 1999). Ramsey et al (Ramsey, Gore et al. 1989) prospectively compared the 
incidence and effect of viral infections on pulmonary function and clinical scores in 15 school-
age patients with CF aged between 5 to 21 years and their healthy siblings. Over a two-year 
period, samples were taken at regular two monthly intervals and during acute respiratory 
illnesses (ARI) for pharyngeal culture and serology for respiratory viruses.  There was a total 
of 68 ARI episodes occurred in the patients with CF and in 19 episodes there was an associated 
virus identified. A total of 49 infective agents were identified either during ARIs or at routine 
testing in the patients with CF; 14 were identified on viral isolation (rhinovirus on 11 
occasions), whilst 35 were isolated on seroconversion (PIV on 12, RSV on 9 and M. pneumoniae 
on 6 occasions). There was no significant difference in the rate of viral infections between the 
patients with CF and their sibling controls, as measured either by culture or serology.  The rate 
of viral infections was higher in younger children (both CF and controls), and the rate of 
decline in pulmonary function was greater in the younger children with CF with more viral 
infections. At the time of an ARI, the virus isolation and seroconversion (fourfold increase in 
titres) rates were 8.8% and 19.1%, respectively in children with CF compared to 15.0% and 
15.0% respectively for the non-affected siblings. In contrast the rates of virus isolation and 
seroconversion at routine 2 monthly visits were 5.6% and 16.2 % respectively for children with 
CF and 7.7% and 20.2% respectively for the healthy siblings. 
Similarly Hiatt (Hiatt, Grace et al. 1999) assessed respiratory viral infections over three winters 
in 22 infants less than two years of age with CF (30 patient seasons), and 27 age matched 
controls (28 patient seasons).  The average number of acute respiratory illness per winter was 
the same in the control and CF groups (5.0 versus 5.0). However, only 4 of the 28 control 
infants had lower respiratory tract symptoms in association with the respiratory tract illness, 
compared with 13 out of the 30 infants  with CF (Odd ratio- 4.6; 95% confidence interval 1.3 
and 16.5; p-value <0.05). 7 of the infants with CF cultured RSV, of whom 3 required 
hospitalisation.  In contrast, none of the controls required hospitalisation.  Pulmonary function 
measured by rapid chest compression technique was significantly reduced in the infants with 
CF after the winter months and was associated with two interactions; RSV infection with 
lower respiratory tract infection and male sex with lower respiratory tract infection. 
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From previous reports, two viral agents appear to have the greatest effect on respiratory 
status in CF, namely RSV and influenza, possibly because the uses of viral culture and 
serology have underestimated the effects of rhinovirus. In younger children, RSV is a major 
pathogen resulting in an increased rate of hospitalisation. Abman et al (Abman, Ogle et al. 
1991) prospectively followed up 48 children with CF diagnosed through newborn screening 
and documented the effect of RSV infection. Eighteen of the infants were admitted into 
hospital a total of 30 times over a mean follow-up of 28 months (range 5-59). In seven of 
these infants RSV was isolated, and their clinical course was severe with 3 requiring 
mechanical ventilation and 5 necessitating chronic oxygen therapy. Over the next 2 years 
these infants had significantly more frequent respiratory symptoms and lower Brasfield 
chest radiograph (Brasfield, Hicks et al. 1979) scores than non-RSV infected counterparts. 
Brasfield scores air trapping on the lateral chest film, and linear markings, nodular cystic 
lesions, large lesions, and general severity on the posteroanterior chest film. Twenty five 
points represent a normal chest radiograph with lower scores indicating increasing disease 
severity. 
In older children and adults with CF, influenza seems to have the greatest effect. Pribble et al 
(Pribble, Black et al. 1990) assessed acute pulmonary exacerbation isolates from 54 patients 
with CF. Over the year of the study, 80 exacerbations were identified, of which 21 episodes 
were associated with an identified viral agent (influenza A- 5 episodes; influenza B- 4 
episodes; RSV- 3 episodes) with most agents identified on serology. Compared to other 
respiratory viruses, infection with influenza was associated with a more significant drop in 
pulmonary function (FEV1 declined by 26% compared with 6%). There were also a higher 
proportion of patients with a greater than 20% drop in FEV1 within the influenza infected 
cohort. A retrospective study in older patients with chronic P. aeruginosa infection reported 
an acute deterioration in clinical status in association with influenza A virus infection 
(Conway, Simmonds et al. 1992). 
Over a 1-year period, Smyth et al (Smyth, Smyth et al. 1995) prospectively investigated 108 
patients with CF (mean age of 7.9 years) using a combination of viral immunofluorescence, 
culture and seroconversion (fourfold increase in titres) to identify respiratory viruses. With 
the exception of rhinovirus, a seminested reverse transcriptase PCR technique was used. 
During the study, 76 subjects had 157 respiratory exacerbations (1.5 episodes/patient/year) 
and a viral agent was identified in 44 episodes, 25 of which were rhinovirus and an equal 
distribution of other viruses identified almost always on seroconversion. Identification of a 
respiratory virus during the course of the year was associated with a significantly greater 
decline in Shwachman score (Shwachman and Kulczycki 1958) and days of intravenous 
antibiotics use. The Shwachman scoring system is an objective measurement of the clinical 
status of cystic fibrosis patients. This score is based on clinical and radiological evaluation 
and represented a milestone in the history of CF. Patients with scores of 90 to 100 are 
classified as ‘excellent’, 80 to 89 as ‘good’, 70 to 79 as ‘fair’, and 50 to 69 reflects a ‘poor’ 
clinical status. In addition, those children in whom a non-rhinovirus was identified had a 
significantly greater decrease in FEV1 over the year of the study. 
Collinson et al (Collinson, Nicholson et al. 1996) followed 48 children with CF over a 15 
month period using viral cultures for viral detection, with the exception of picornaviruses 
where PCR was used.  children completed the study and there were 147 symptomatic 
upper respiratory tract infections (2.7 episodes/child/year), with samples available for 119 
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episodes. Picornaviruses were identified in 51 (43%) of these episodes, of which 21 (18%) 
were rhinoviruses. In those children old enough to perform spirometry, there were 
significant reduction in both FVC and FEV1 in association with URTIs, with little difference 
in severity of reduction whether a picornavirus was identified or not. Maximal mean drop 
in FEV1 was 16.5%, at 1-4 days after onset of symptoms, but a deficit of 10.3% persisted at 
21-24 days. Those with more URTIs appeared to have greater change in total Shwachman 
score (Shwachman and Kulczycki 1958) and Chrispin-Norman score (Chrispin and Norman 
1974) over the study. Chrispin-Norman score (Chrispin and Norman 1974)is a standardized 
scoring system to assess the severity of CF lung disease on chest radiograph and to allow 
longitudinal follow-up. Six children isolated a P.aeruginosa for the first time during the 
study, 5 at the time of a URTI and only 1 was asymptomatic at the time of first isolation. 
However, the data from this study has to be handled with care as the term ‘upper 
respiratory tract illness-URTI’ did not necessarily imply a positive viral isolation. 
Punch et al (Punch, Syrmis et al. 2004) used a multiplex reverse transcriptase PCR (RT-PCR) 
assay combined with an enzyme-linked amplicon hybridization assay (ELAHA) for the 
identification of seven common respiratory viruses in the sputum of 38 CF patients. 53 
sputum samples were collected over 2 seasons and 12 (23%) samples from 12 patients were 
positive for a respiratory virus (4 for influenza B, 3 for parainfluenza type 1, 3 for influenza A 
and 2 for RSV). There were no statistical associations between virus status and 
demographics, clinical variables or isolation rates for P. aeruginosa, S. aureus or A. fumigatus.  
Olesen and colleagues (Olesen, Nielsen et al. 2006) obtained sputum/laryngeal aspirates 
from children with CF over a 12 month period in outpatient clinics. They achieved a viral 
detection rate of 16%, with rhinovirus being the most prevalent virus. FEV1 was significantly 
reduced during viral infection (-12.5%, p=0.048), with the exception of rhinovirus infection. 
The authors were not able to demonstrate a positive correlation between respiratory viruses 
and bacterial infections in their studied population as the type or frequency of bacterial 
infection during or after viral infections were not altered. They also concluded that clinical 
viral symptoms had a very poor predictive value (0.39) for a positive viral test. 
Wat et al (Wat, Gelder et al. 2008) utilised ‘real-time’ Nucleic Acid Sequenced Based 
Amplification to examine the role of respiratory viruses in CF. They achieved the highest 
detection rate of 46% amongst all existing literature concerning respiratory viruses in the CF 
population during reported episodes of respiratory illness. The results compare favourably 
with previous studies and this may be that earlier studies relied heavily on repeated 
serological testing, either alone(Petersen, Hoiby et al. 1981) or in combination with viral 
isolation (Wang, Prober et al. 1984; Ramsey, Gore et al. 1989; Pribble, Black et al. 1990; 
Armstrong, Grimwood et al. 1998; Hiatt, Grace et al. 1999). They also achieved a viral 
detection rate of 18.3% from routine nasal samples and this is comparable to the 
seroconversion rate of 12.3% as reported by Wang et al(Wang, Prober et al. 1984). This value 
is similar to the seroconversion rate of 16.2% from asymptomatic samples achieved by 
Ramsey and colleagues(Ramsey, Gore et al. 1989). Amongst stable asthmatic children, 
Johnston et al (Johnston, Pattemore et al. 1995) found a viral detection rate of 12% by PCR.  
Therefore, a laboratory method with a higher sensitivity for viral detection used in this 
study has not increased the detection rate in asymptomatic samples, implying that the high 
detection rate of respiratory viruses during exacerbations reinforces their pathogenicity. The 
authors also demonstrated that influenza A and B viruses are major viruses in causing 
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respiratory exacerbations in CF and both viruses are more commonly detected during 
pulmonary exacerbations. 22 of 88 (23%) viruses found in this study are influenza viruses (A 
& B). The result is consistent with majority of the previous studies which showed that 
influenza virus represented between 12 to 27% of all viruses detected. In relation to influenza 
vaccination, the uptake rate was up to 70% during the 2003/4 season (Wat, Gelder et al. 
2008) and the significance is that the influenza detection rate in this study could easily have 
been higher had the vaccination uptake rate in the study not been this high.  
In 2009, a novel swine pandemic influenza A virus (H1N1) was identified. To date very little 
data exists regarding its impact on patients with CF. Nash et al (Nash, Whitmill et al. 2011) 
showed the symptoms of CF patients infected with H1N1 tend to be mild. There was no 
significant reduction in FEV1 % predicted, FVC % predicted and body mass index regardless 
of whether the patients were positive or negative for H1N1. Colombo et al (Colombo, 
Battezzati et al. 2011) performed a multi-centre survey showed that diagnostic testing did 
not identify clinical characteristics specifically associated with H1N1 infections. Similarly, 
they did not show a significant decline in lung function associated with this infection. 
Experimental data on the effects of viral infections in CF are limited. Toll-like receptors 
(TLRs) have recently been identified as key mediators of the innate response and they 
recognise pathogens through detection of conserved microbial structures that are absent 
from the host. Kurt-Jones et al (Kurt-Jones, Popova et al. 2000) found that RSV persisted 
longer in the lungs of infected TLR4-deficient mice compared to normal mice. Haynes et al 
(Haynes, Moore et al. 2001) also demonstrated that TLR4-deficient mice when challenged 
with RSV exhibited impaired natural killer cell trafficking and impaired virus clearance 
compared to normal ones. Limited human studies have demonstrated the important role of 
TLRs in host response against many major groups of mammalian pathogens(Qureshi and 
Medzhitov 2003). The relationship between TLR and respiratory virus including RSV in 
humans will require further studies before it can be established.  
Some studies have suggested a higher viral replication when there is an impairment of the 
innate host defence in CF. Influenza titres were significantly increased in a mouse model 
which were chronically infected with P. aeruginosa compared to control model (Seki, 
Higashiyama et al. 2004). Increased virus replication was also found after PIV infection of 
CF human airway epithelial cells, compared to controls (Zheng, De et al. 2003). One of the 
possible causes of increased virus replication and of virus persistence might be a reduced 
production of respiratory nitric oxide (NO), which is a vital part of innate antiviral defence 
mechanism (Zheng, Xu et al. 2004). Increased production of NO protects against viral 
infections. In CF patients, expression of the NO producing enzyme NO synthase type 2 
(NOS2) is considerably reduced. 
3. Detection of respiratory viruses 
The principal laboratory methods of respiratory virus diagnosis rely on their detection in 
respiratory secretions and another important factor in respiratory viral diagnosis is to 
submit an appropriate sample for testing. Inappropriate specimen collection and transport 
account for the largest source of error in the accuracy of viral detection results (Nutting, 
Main et al. 1996).  Nasal swabs, nasopharyngeal aspirates, nasal wash and sputum 
specimens are generally considered as the specimens of choice for the detection of 
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respiratory viruses (Hall and Douglas 1975; Schmid, Kudesia et al. 1998; Covalciuc, Webb et 
al. 1999; Punch, Syrmis et al. 2004). Performing a nasopharyngeal aspirate or suction can be 
unpleasant and requires the use of a suction device by a trained individual, which makes it 
unattractive in widespread clinical applications. In contrast, the collection of a nasal swab is 
simple, painless and quick and it does not require special equipment and skilled personnel. 
A prospective study by Heikkinen et al showed that the sensitivity of nasal swabs was 
comparable to nasopharyngeal aspirates for the detection of all major respiratory viruses by 
tissue culture with the exception of RSV (Heikkinen, Marttila et al. 2002). In non-sputum 
producing patients with CF, it has been shown that throat swab is not inferior to 
nasopharyngeal suction in detecting pathogens (Taylor, Corey et al. 2006). 
Molecular techniques have superseded many ‘conventional’ methods utilised for respiratory 
viral detection such as viral culture and serology analysis due to their rapid turn-around of 
results. Traditional virus culture and serology analysis may require 1 to 2 weeks before 
results are available and direct antigen detection can have variable sensitivity and specificity 
(Swierkosz, Erdman et al. 1995). Molecular assays also have particular advantages where the 
starting material available is acellular (swab) or where surveillance samples have a low copy 
number of the viral target. The rapid turn-over of results allowing diagnostic virology to 
have an impact on patient management, avoiding the inappropriate prescription of 
antibiotics and allowing the proper use of anti-virals. It may also play an important role in 
infection control in the hospital setting.  
More recently, Virochip has been shown to be a pan-virus microarray platform that is 
capable of detection of known as well as novel viruses in a single assay simultaneously 
(Chiu, Rouskin et al. 2006). The Virochip is very much a research tool at present, and several 
issues must be addressed before it can be used on a routine basis for virus detection in the 
clinical setting. These issues include cost, accuracy, reproducibility, and 
sensitivity/specificity for virus detection in comparison with traditional laboratory 
techniques. In addition, the implication of novel viruses in the human respiratory tract is not 
yet defined.  
4. Interaction between respiratory viruses and bacteria 
In a 25 year retrospective review from the Danish CF clinic, the first isolation of P. aeruginosa 
was most likely between October and March (Johansen and Hoiby 1992) coinciding with the 
peak of the RSV season. These findings must be interpreted with caution by the design of 
the study, as there are a number of other possible agents that would broadly fit the RSV 
season, most notably influenza, rhinovirus and metapneumovirus. 
An increase in immunoglobulin A (IgA) antibodies to the O-antigen of P. aeruginosa is noted 
in 62% of viral infections (Przyklenk, Bauernfeind et al. 1988). This suggests a possible 
‘microbial synergism’ between bacterial infections and infections with respiratory viruses in 
CF. 
The first bacterial isolation of a given organism in CF has also been shown to often follow a 
viral infection. In the 17 month prospective study reported by Collinson et al (Collinson, 
Nicholson et al. 1996), five of the six first isolations of P. aeruginosa were made during the 
symptomatic phase of an upper respiratory tract infection or three weeks thereafter.  In 
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contrast only one of the six initial infections with P. aeruginosa was identified during the 
asymptomatic period.  Similarly, H. influenzae was recovered for the first time from 3 
children within 3 weeks of an upper respiratory tract infection and the one new S. aureus 
infection was identified immediately following a viral infection.  
Armstrong and colleagues have reported that 50% of CF respiratory exacerbations requiring 
hospitalisation are associated with isolation of a respiratory virus (Armstrong, Grimwood et 
al. 1998). In their prospective study of repeated bronchoalveolar lavage (BAL) in infants 
over a 5 year period, a respiratory virus was identified in 52% of infants hospitalised for a 
respiratory exacerbation, most commonly RSV. 11 of the 31 hospitalised infants (35%) 
acquired P. aeruginosa in the subsequent 12-60 month follow up, compared to 3 of 49 (6%) 
non-hospitalised infants (Relative risk 5.8). 
Respiratory viruses can disrupt the airway epithelium and precipitate bacterial adherence. 
Influenza A infection has been shown to cause epithelial shedding to basement membrane 
with submucosal oedema and neutrophil infiltrate (Walsh, Dietlein et al. 1961), while both 
influenza and adenovirus have a cytopathic effect on cultured nasal epithelium leading to 
destruction of the cell monolayer (Winther, Gwaltney et al. 1990). This epithelial damage 
results in an increase in the permeability of the mucosal layer (Igarashi, Skoner et al. 1993; 
Ohrui, Yamaya et al. 1998) and possibly facilitating bacterial adherence. Bacteria can also 
utilise viral glycoproteins and other virus induced receptors on host cell membrane as 
bacterial receptors in order to adhere to virus infected cells (Sanford, Shelokov et al. 1978; 
Raza, Essery et al. 1999). 
Kim et al (Kim, Battaile et al. 2008) found that invariant natural killer T cells induce a type of 
macrophage activation driving the secretion of interleukin-13 leading to the production of 
globlet cell metaplasia and airway hyperactivity following infection with Sendai virus. The 
term ‘invariant’ stems from the fact that all invariant natural killer T cells in humans and 
mice use a unique T cell receptor that is essential for interaction with CD1d. CD1d molecules 
present lipid antigens to T lymphocytes rather than peptide antigens as in the case of major 
histocompatibility-complex (MHC) class I and II molecules. Historically, MHC class II 
dependent CD4 and T lymphocytes, through their response to stimulation by environmental 
allergens, are keys to the pathogenesis of human asthma. The findings by the authors lead to 
the notion of the use of anti-interleukin-13 therapy as a potential therapy in patients. 
Viral infections might predispose to secondary bacterial infections by impairing mucociliary 
function and triggering host inflammatory receptors (Wilson and Cole 1988; Murphy and Sethi 
1992). This phenomenon has been demonstrated both in vivo and in vitro (Jiang, Nagata et al. 
1999; White, Gompertz et al. 2003). Avadhanula et al (Avadhanula, Rodriguez et al. 2006) 
showed that different respiratory viruses use different mechanisms to enhance the adherence 
of bacteria to respiratory epithelial cells. In particular RSV and PIV type 3 upregulate 
intercellular adhesion molecule-1 (ICAM-1), carcinoembryonic adhesion molecule 1 
(CEACAM1) and platelet activating factor receptor (PAFr) but not mucin on the surfaces of 
A549, BEAS-2B and NHBE but not SAE cell lines. Much of the increased bacterial adhesion 
following RSV infection could be blocked by antibodies directed against these receptors. A549 
and BEAS-2B are transformed cell lines derived from type II alveolar and normal bronchial 
cells, respectively. NHBE and SAE cells and primary epithelial cells obtained from bronchi and 
distal bronchial tree and are likely to include a heterogeneous population of cells. 
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Mechanisms independent of the expression of conventional receptors for bacteria, such as 
binding to viral proteins, could be responsible for enhanced adhesion (Hament, Kimpen et 
al. 1999). Immunofluorescence microscopy demonstrates that bacteria binding to RSV 
infected A549 cells adhere not only to these cells expressing viral antigens but also to 
uninfected epithelial cells. These data suggest that the ability to augment bacterial adhesion 
may result from a factor served by infected cells that exert a paracrine effect on adjacent 
epithelium. Cytokines or other inflammatory molecules are potential good candidates for 
such a mediator. 
Rhinovirus has been shown to potentiate bacterial infections by inhibiting the secretion of 
TNF alpha and interleukin-8 by macrophages in vitro following co-infection with gram 
negative bacterial products, lipopolysaccharide (LPS), and gram positive bacterial products, 
lipoteichoic acid (LTA) (Oliver, Lim et al. 2008). This rhinovirus dependent impairment of 
the macrophage immune response was not mediated by autocrine production of the anti-
inflammatory cytokines interleukin-10 and PGE2, or by downregulation of the cell surface 
receptor for LTA and LPS. In addition, the authors also show that rhinovirus inhibit the 
phagocytosis of bacterial products by macrophages. These findings support the notion that 
rhinovirus exposure resulted in a reduced ability to innate and adaptive immune responses 
against bacterial products, hence promoting the occurrence of bacterial and viral co-
infections. 
The lower respiratory tract is protected by local mucociliary mechanisms that involve the 
integration of the ciliated epithelium, periciliary fluid and mucus. Mucus acts as a physical 
and chemical barrier onto which particles and organisms adhere. Cilia lining the respiratory 
tract propel the overlying mucus to the oropharynx where it is either swallowed or 
expectorated. Influenza viral infection has been shown to precipitate the loss of cilial beat, 
and shedding of the columnar epithelial cells generally within 48 hours of infection 
(Thompson, Barclay et al. 2006). Pittet et al (Pittet, Hall-Stoodley et al.) showed that a prior 
influenza infection of tracheal cells in vivo does not increase the initial number of pneumococci 
found during the first hour of infection, but it does significantly reduce mucociliary velocity, 
and thereby reduces pneumococcal clearance during the first 2 hours after pneumococcal 
infection at both 3 and 6 days after an influenza infection. The defects in pneumococcal 
clearance were greatest at 6 days after influenza infection. Changes to the tracheal epithelium 
induced by influenza virus may increase susceptibility to a secondary S. pneumoniae infection 
by increasing pneumococcal adherence to the tracheal epithelium and/or decreasing the 
clearance of S. pneumoniae via the mucociliary escalator of the trachea, and thus increasing 
the risk of secondary bacterial infection. 
De Vrankrijker et al (de Vrankrijker, Wolfs et al. 2009) showed that mice that were co-infected 
with RSV and P. aeruginosa had a 2,000 times higher colony-forming units (CFU) counts of 
Pseudomonas aeruginosa in the lung homogenates compared to mice that were infected with 
P. aeruginosa alone. Co-infected mice also had more severe lung function changes. These 
results suggest that RSV can facilitate the initiation of acute P. aeruginosa infection. 
Another study also showed that H. influenzae and S. pneumoniae bind to both free RSV 
virions and epithelial cells transfected with cell membrane-bound G protein, but not to 
secreted G protein. Pre-incubation with specific anti-G antibody significantly reduce 
bacterial adhesion to G protein-transfected cells (Avadhanula, Wang et al. 2007). 
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Stark et al (Stark, Stark et al. 2006) showed that mice that were exposed to RSV had 
significantly decreased S. pneumonia, S. aureus or P. aeruginosa clearance 1 to 7 days after 
RSV exposure. Mice that were exposed to both RSV and bacteria had a higher production of 
neutrophil-induced peroxide but less production of myeloperoxidase compared to mice that 
were exposed to S. pneumoniae alone. This suggests that functional changes in the recruited 
neutrophils may contribute to the decreased bacterial clearance. 
More recently, Chattoraj et al (Chattoraj, Ganesan et al., 2011) demonstrated that acute 
infection of primary CF airway epithelial cells with rhinovirus liberates planktonic bacteria 
from biofilm. Superinfection with rhinovirus stimulates robust chemokine responses from CF 
airway epithelial cells that were pretreated with mucoid P. aeruginosa. The authors also 
showed that these chemokine responses lead to a liberation of bacteria from mucoid P. 
aeruginosa biofilm and transmigration of planktonic bacteria from the apical to the 
basolateral surface of mucociliary-differentiated CF airway epithelial cells. Planktonic 
bacteria, which are more proinflammatory than their biofilm counterparts, stimulate 
increased chemokine responses in CF airway epithelial cells which, in turn, may contribute 
to the pathogenesis of CF exacerbations and subsequent prolonged intravenous antibiotic 
use and hospitalisation. 
Taken together, these findings suggest that respiratory viruses may lead to epithelial 
disruption, increased or decreased cytokine production, neutrophil influx, inhibition of 
macrophage phagocytosis, destruction of mucociliary escalator, increased cytokine 
production, and increased neutrophil induced peroxide release, indirectly facilitating 
bacterial infection of the airway.  
5. Prevention and treatment for respiratory viruses 
The existence of diverse viral serotypes in causing infection has made vaccine preparation 
very difficult. Frequent mutations of viral proteins of RNA viruses (for example genetic drift 
and shift of influenza) have further hampered the prevention of the illness. 
Influenza associated death is between 13,000 to 20,000 per year in the winter months in the 
UK (Fleming 1996), though some of the deaths may be attributed to RSV.  Influenza vaccines 
are the only commercially available vaccines against common respiratory viruses. They have 
been used since mid 1940s and they now have an established role in prevention of influenza 
A and B infections. Inactivated influenza vaccine is effective even in young children including 
those younger than 2 years (Heinonen, Silvennoinen et al. 2010). The waning of vaccine-
induced immunity over time requires annual re-immunisation even if the vaccine antigens 
are unchanged. 
Recent vaccines contain antigens of two influenza A subtypes, strains of the currently 
circulating H3N2 and H1N1 (Swine flu) subtypes, and one influenza B virus. The current 
recommendation for influenza vaccination in the UK is to offer it to those over the age of 65, 
those with chronic heart, respiratory (including CF) or renal diseases and those who are 
diabetic or immunosuppressed.  
Wat et al (Wat, Gelder et al. 2008) recently showed that influenza vaccination provides 
protection against influenza acquisition in patients with CF, with 1 of 41 patients vaccinated 
had a positive nasal swab for influenza compared to 4 of the 22 non-vaccinated patients 
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(p=0.046). Although influenza vaccination does not appear to have any impact on respiratory 
exacerbation rates, it does have a role in preventing live infections. In this study, respiratory 
exacerbation rates in the preceding 10 months before the study between the vaccinated and 
non-vaccinated groups were similar, indicating that these were unlikely to be the reasons 
influencing the decision on immunisation. The decision may be down to a combination of 
patient/ parent education, social background, awareness of vaccination and accessibility of 
vaccination.  
Due to the lack of randomised controlled studies looking at the efficacy of influenza vaccine 
in CF, the Cochrane review recommends clinicians to make their own judgements on the 
benefits and risks of this therapy in this cohort of patients (Dharmaraj and Smyth 2009). In 
addition to vaccine, neuraminidase inhibitors have been shown to have a role in preventing 
influenza A and B infections (Harper, Bradley et al. 2009). 
Rhinovirus has more than 100 serotypes; it is unlikely that a unifying vaccine will be 
developed. VP4, one of the nonenveloped capsids, is highly conserved among all of the 
rhinoviruses; anti-VP4 antibodies have recently been generated and been shown to have the 
potential for future vaccine development(Katpally, Fu et al. 2009).  
The development of an RSV vaccine has been hampered by the experience with formalin-
inactivated whole RSV vaccine in the 1960s, as it caused 80% of RSV vaccinees to become 
hospitalised compared with 5% of controls, as well as two fatalities (Kim, Canchola et al. 
1969). Current major research work has focused on a prophylaxis using a humanised mouse 
monoclonal antibody, Palizivumab. In patients with CF, monthly Palizivumab injection 
significantly reduce the hospitalisation rate for acute respiratory illness during the RSV 
season compared to those who were not immunised (p<0.05). The former group also had 
fewer hospital days for acute respiratory illness (Giebels, Marcotte et al. 2008). 
There is currently no licensed PIV vaccine to date. The formalin-inactivated vaccine 
generated in the 1960s was not able to prevent PIV infection and was soon abandoned. 
Recently, recombinant bovine PIV type 3 and human PIV type 3 attenuated vaccines are 
being evaluated in animal models as vectors for the delivery of other viral antigens such as 
RSV-G and RSV-F proteins. This bivalent vaccine combination provides high level of 
resistance to challenges with PIV type 3 and RSV in animal models (Schmidt, McAuliffe et al. 
2001).  
The conventional methods of vaccination are via the intramuscular and subcutaneous 
routes. Mucosal immunisation has recently been explored as it represents an attractive 
manner of delivering vaccines. It is fast, simple, non-invasive and can be carried out by 
unskilled individuals. The use of mucosal vaccination seems logical in that most of 
respiratory viral infections initially start at the mucosal sites and therefore inducing local 
immunity. 
So far, there has been inconclusive evidence to support the use of vitamin C and extracts of 
the plant Echinacea in common cold prevention. Daily supplementation with large doses of 
vitamin C does not seem to prevent common colds, however there seems to be a modest (8 
to 9%) reduction in the number of symptom days in individuals with established cold 
symptoms, with larger doses having greater effect (Douglas, Chalker et al. 2000). In vitro 
studies have shown that Echinacea can activate macrophages, increase phagocytosis, 
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enhance cytokine production (Sharma, Arnason et al. 2006), and natural killer cell activity, 
and improve lymphocyte and monocyte cell counts (Goel, Lovlin et al. 2005). Current data is 
available in the adult population and has reported positive findings both in the treatment 
and prevention of upper respiratory tract infection. However, variations in the design of the 
clinical trial and in Echinacea preparations have to be taken into account (Giles, Palat et al. 
2000).  
Zinc has been shown to possess anti-viral properties in vitro and different preparations of 
zinc have been proposed for the treatment of common cold. Postulated mechanisms in the 
common cold include interfering with rhinovirus protein cleavage or capsid binding to 
ICAM-1 in nasal epithelium (Novick, Godfrey et al. 1996). Zinc lozenges appeared to have 
positive effects on adults but negative effects on children in terms of duration and severity 
of common cold symptoms (Macknin, Piedmonte et al. 1998; Marshall 2000). Higher doses 
were found to have a greater impact in reduction of symptom duration and reduced 
symptom severity (Godfrey, Conant Sloane et al. 1992; Mossad, Macknin et al. 1996). Zinc 
nasal spray appears to reduce the total symptom score but has no effect on the duration of 
common cold (Belongia, Berg et al. 2001). Irritation by nasal sprays limits their use; they also 
seem to have lower concentrations in the nasopharynx (Godfrey 1988).   
Amantadine has been the conventional anti-viral against influenza. However it is strain 
specific as it is only effective against influenza A and has common side-effects such as 
insomnia, poor concentration and irritability. It is now largely being replaced by 
neuraminidase inhibitors such as Zanamivir and Oseltamivir which are licensed for the 
treatment of influenza A and B, including avian flu H5N1 and swine flu H1N1. However, 
Amantadine still has a role in dealing with Oseltamivir resistant H1N1 virus. In children 
and adults, early initiation of neuraminidase inhibitors within 48 hours of the onset of 
symptoms can reduce the duration of flu-like symptoms by 0.5 to 2.5 days (Shun-Shin, 
Thompson et al. 2009). Early use of these medications can also reduce development of 
complications such as pneumonia (Yu, Liao et al. 2010). The 2009 pandemic H1N1 virus 
remains susceptible to neuraminidase inhibitors, and Oseltamivir has been used extensively 
for treatment related to this viral infection. Resistance to Oseltamivir has been reported with 
H1N1 viral infection but this is mainly restricted to immunocompromised individuals 
(Bautista, Chotpitayasunondh et al. 2010). Zanamivir has a poor oral bioavailability, and 
intranasal application has been shown to be effective in treating experimental influenza 
infection with the reduction in symptoms caused, virus shedding and development of otitis 
media (Hayden, Treanor et al. 1996). Intravenous use of Peramivir or Zanamivir could be 
lifesaving in critically ill patients with influenza infection (Birnkrant and Cox 2009; Harter, 
Zimmermann et al. 2010). 
Ribavarin, a synthetic guanosine nucleoside that has a broad spectrum of antiviral activity, 
has been used for treatment of infections related to RSV, metapneumovirus, and parainfluenza 
and influenza viruses (Yin, Brust et al. 2009). Potential benefits of ribavarin therapy include 
the inhibition of RSV-specific IgE production in nasal secretions, which has been associated 
with the development of hypoxaemia and wheezing (Rosner, Welliver et al. 1987) and it has 
improved pulmonary functions (Hiatt 1990). Controlled studies also show that the use of 
ribavarin is effective in reducing the clinical severity score, duration of mechanical 
ventilation, supplemental oxygen use and days of hospitalisation (Smith, Frankel et al. 
1991). Aerosolised ribavarin has been used for the treatment of RSV related bronchiolitis 
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and pneumonia. Intravenous formulation could be used for treatment of severe pneumonia, 
caused by infection RSV, metapneumovirus, or parainfluenza virus, on the basis of experience 
in immunocompromised patients (Hopkins, McNeil et al. 2008). Bonney et al has shown that 
metapneumovirus can be successfully treated with a combination of intravenous ribavarin 
and immunoglobulin (Bonney, Razali et al. 2009). 
Although rhinovirus is the major cause of colds, its vast amount of serotypes has made 
development of anti-virals against it problematic. 90% of rhinovirus serotypes gain entry into 
epithelial cells using ICAM-1 cellular receptors and blockade of these receptors in 
experimental studies have shown reduced infection severity (Turner, Wecker et al. 1999), 
but further study is required before this treatment option becomes widely available. 
Macrolide antibiotics, Bafilomycin A1 and Erythromycin have been shown to inhibit ICAM-
1 epithelial expression and hypothesis about their potential as anti-inflammatory agents 
have yet to be definitive, as clinical proof is either negative or inconclusive (Suzuki, Yamaya 
et al. 2002). 
Recently, an anti-rhinoviral agent known as Plecoranil, which acts by inhibiting the 
uncoating of Picornaviruses (Ledford, Patel et al. 2004), the RV 3C protease inhibitor, 
Ruprintrivir(Hayden, Turner et al. 2003) and soluble ICAM-1, Tremacamra(Turner, Wecker 
et al. 1999) have shown promising results in early-stage clinical trials, but each of these 
medications was derailed by a combination of cost, pharmacokinetics, toxicity, drug 
interactions, and limited efficacy (Turner 2005). 
6. Conclusion 
With the available knowledge regarding the impact of respiratory viruses in the 
exacerbation of CF, screening for respiratory viruses during pulmonary exacerbations 
should be implemented as part of routine clinical assessment. This assessment should 
include obtaining specimens from the respiratory tract and using molecular viral detection 
methods to reach a rapid diagnosis. The identification of respiratory viruses may allow 
appropriate anti-virals to be used.  
With gene therapy still undergoing further research with regards to its validity and 
specificity, gaining further understanding in the pathogenesis of virus induced respiratory 
exacerbations in CF may allow the development of new therapeutic techniques. If viral 
infection does predispose to bacterial infection, then influencing the interaction between 
viruses and bacteria could be a next pathway to diminish respiratory morbidity in patients 
with CF. The development of novel therapies will be exciting and this may further prolong 
the lifespan of patients with CF and more importantly improve their quality of life. 
In light of the above, future research in respiratory viruses in CF is urgently required to 
address a number of important questions: 1) What is the optimal way for viral sampling? 2) 
What is the most efficient and rapid method to detect a range of respiratory viruses? 3) How 
do respiratory viruses influence bacterial behaviour in chronically infected airways? 4) What 
is the efficacy of influenza vaccination in CF? 5) What are the roles of anti-virals in CF? 
Further understanding in the pathogenesis of viral infection in CF would be beneficial as 
this may provide insight to the above unresolved mysteries. At the moment it appears that 
influenza vaccination remains the mainstay of management of viral infections in CF. 
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